BioScrip Inc. (BIOS) Trading Down 1.1%
BioScrip Inc. (NASDAQ:BIOS)’s share price fell 1.1% on Monday . The stock traded as low as $2.65 and last traded at $2.70, with a volume of 326,783 shares changing hands. The stock had previously closed at $2.73.
Separately, Zacks Investment Research raised BioScrip from a “sell” rating to a “hold” rating in a research note on Friday, June 17th.
The stock’s market capitalization is $310.89 million. The company’s 50 day moving average is $2.63 and its 200 day moving average is $2.40.
BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.05. The firm earned $232.50 million during the quarter, compared to analyst estimates of $229.58 million. The company’s revenue for the quarter was down 11.4% on a year-over-year basis. Equities analysts expect that BioScrip Inc. will post ($0.22) earnings per share for the current year.
In other news, Director Coliseum Capital Management, L purchased 4,200,000 shares of the business’s stock in a transaction dated Wednesday, June 22nd. The shares were acquired at an average price of $2.00 per share, with a total value of $8,400,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David W. Golding purchased 12,500 shares of the business’s stock in a transaction dated Friday, June 17th. The shares were purchased at an average cost of $2.48 per share, for a total transaction of $31,000.00. Following the purchase, the director now directly owns 42,500 shares of the company’s stock, valued at $105,400. The disclosure for this purchase can be found here.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.